Role of central epinephrine in regulation of anterior pituitary hormone secretion by Terry, L. Cass et al.
Peptides, Vol. 3, pp. 311-318, 1982. Printed in the U.S.A. 
Role of Central Epinephrine in Regulation 
of Anterior Pituitary Hormone Secretion I 
L. CASS TERRY, z W. R. CROWLEY, a C. LYNCH, C. LONGSERRE 
AND M. D. JOHNSON 
VA Medical Center and Department o f  Neurology, University o f  Michigan, Ann Arbor, MI 48105 
and Department o f  Pharmacology, University o f  Tennessee Center for  Health Sciences, Memphis, TN 38163 
TERRY, L. C., W. R. CROWLEY, C. LYNCH, C. LONGSERRE AND M. D. JOHNSON. Role of central epinephrine in 
regulation of anterior pituitary hormone secretion. PEPTIDES 3(3) 311-318, 1982.--Hypothalamic regulation of anterior 
pituitary hormones is thought to be mediated by the release of stimulatory and/or inhibitory peptides that are, in turn, 
regulated by catecholaminergic neurons. The recent development of selective epinephrine (EPI) synthesis inhibitors has 
made it possible to disrupt central EPI neurotransmission without affecting norepinephrine or dopamine. These compounds 
were used in the present investigation to assess the involvement of brain EPI systems in regulation of GH, LH, and 
prolactin (PRL) in male and ovariectomized female rats. Inhibition of central EPI synthesis (1) inhibited episodic and 
morphine-, but not clonidine-induced GH release, and (2) blocked the LH surge induced by estrogen and progesterone, but 
did not affect episodic LH release in hormonally untreated rats. Inhibition of peripheral (adrenal) EPI synthesis had no 
effect on these hormones. Results of these studies suggest an excitatory role for EPI in regulation of GH and LH secretion, 
mediated by stimulation of GH-releasing hormone and LHRH, respectively. EPI does not appear to have a major function 
in regulation of PRL secretion. 
Epinephrine Growth hormone Luteinizing hormone Prolactin Neurotransmitters Hypothalamus 
THE hypothalamus contains a number of  neurotransmitters 
and the enzymes involved in their synthesis. There is grow- 
ing evidence that these substances modulate hypothalamic 
peptidergic nerve function or are themselves released into 
the portal system to act on pituitary receptors and thereby 
influence hormone release. 
Substantial quantities of  dopamine (DA) and norepineph- 
rine (NE) are found in the median eminence and in various 
hypothalamic nuclei of  the rat [14, 33, 34, 38]. Epinephrine 
(EPI) and the EPI-forming enzyme, norepinephrine-N- 
methyltransferase (NMT) are also found in the hypothala- 
mus [12, 14, 20, 34]. These neurotransmitters are concen- 
trated in the same regions of  the hypothalamus and median 
eminence that are rich in regulatory peptides [14], suggesting 
a functional relationship. 
Growth hormone (GH) secretion by the pituitary gland 
appears to be regulated by two hypothalamic hormones, one 
stimulatory (GH-releasing factor) and the other inhibitory 
(somatostatin, SRIF). Although there is substantial physi- 
ological and biochemical evidence for the existence of  GH- 
releasing factor, its structure has not been determined [29]. 
Somatostatin has been characterized as a tetradecapeptide 
[2]. Extensive studies in man and experimental animals 
suggest that the release of  SRIF and GH-releasing factor is 
regulated by catecholamine-containing neurons in the central 
nervous system (CNS) [28,29]. 
CNS alpha-adrenergic receptor  stimulation with clonidine 
elicits GH relefise in man [26] and a number of lower species 
[3, 9, 26, 50, 51]. Evidence concerning the role of  brain DA 
receptors in GH control is less consistent. In man, CNS DA 
receptor  stimulation causes GH release [23]. However ,  ac- 
tivation or  blockade of  DA receptors in experimental animals 
has little effect on GH [3, 9, 26], indicating that its effects 
may be specific to man. 
Previous investigations have demonstrated that NE syn- 
thesis inhibitors and receptor  antagonists prevent preovula- 
tory and estradiol plus progesterone-induced surges of  
luteinizing hormone (LH) and prolactin (PRL) [6, 16--18]. 
This has led to the hypothesis that the stimulatory feedback 
actions of  the ovarian hormones, estradiol and progesterone, 
on L H  and PRL secretion involve activation of  central 
noradrenergic systems, which in turn regulate luteinizing 
hormone-releasing hormone (LHRH) release [43]. 
Extensive evidence indicates that DA is important in the 
control of  prolactin PRL secretion in animals and man, and 
that DA is most likely PRL inhibiting factor [21, 22, 27]. The 
role of  the central NE system in regulation of  PRL secretion 
is not clear and the available information is contradictory. 
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Systemic administration of clonidine to experimental 
animals causes elevation of PRL levels [9, 25, 48, 51]. Ad- 
ministration of phenoxybenzamine has a similar effect, 
whereas alpha-blockade with phentolamine or beta-blockade 
with propranolol has no consistent influence [25,30]. 
In the studies described above, noradrenergic agonists 
and antagonists used may also have affected transmission in 
EPI (adrenergic) systems. Results of earlier experiments 
suggest that EPI stimulates GH release in primates [32] and 
rodents [36,37] but not in man [36,42]. This catecholamine is 
also a potent stimulant of LH release in rats [43], whereas its 
role in regulation of PRL secretion is unknown. 
The availability of several selective EPI synthesis in- 
hibitors, developed for possible use as antihypertensive 
agents in man [10, 39, 40, 45], have made it possible to alter 
the synthesis of EPI without affecting NE or DA. These 
compounds have been used in the present investigation to 
assess the involvement of brain EPI systems in regulation of 
GH, LH and PRL secretion in the rat. Results of these 
studies indicate that the CNS adrenergic system has a major 




Male and ovariectomized female Sprague-Dawley rats 
(300-500 g) were housed in temperature- and humidity- 
controlled laboratories with a 12-12 or 14--10 hr light-dark 
cycle (lights on at 0600). The animals were given free access 
to laboratory chow and water. 
Norepinephrine-N-Methyltransferase (NMT, EC2.1.1.28) 
Inhibitors 
The selective EPI synthesis inhibitors, SK&F 64139, 
83593 and 29661 (7,8-dichloro-l,2,3,4-tetrahydroisoquino- 
line, chloro-tetrahydroisoquinoline-7- sulfonamide, and 
1,2,3,4-tetrahydroisoquinoline-7-sulfonamide, respectively; 
Smith, Kline & French Laboratories, Philadelphia, PA), 
which act by inhibiting NMT, were dissolved in 0.15 M NaC1 
(pH 7.0) to yield a final concentration of 25 mg/ml and ad- 
ministered intraperitoneally in doses of 10, 25, and 50 mg/kg 
body weight. A fourth NMT inhibitor, LY 78335 (2,3- 
dichloro-a-methylbenzylamine; Eli Lilly and Company Re- 
search Laboratories, Indianapolis, IN) was dissolved in the 
same vehicle and administered intraperitoneally in doses of 
25 and 50 mg/kg body wt. SK&F 64139, 83593 and LY 78335 
cross the blood-brain barrier and inhibit central and periph- 
eral EPI synthesis [10,45]. SK&F 29661 inhibits only periph- 
eral EPI synthesis, because it does not cross the blood-brain 
barrier [40]. 
Experimental Procedure 
Experiment 1. Chronic indwelling cannulae were placed 
in the right atrium via the right external jugular vein and 
adapted to isolation test chambers by methods described 
previously [50]. Blood samples were withdrawn every 15 min 
and centrifuged immediately. The plasma was frozen at 
-90°C until radioimmunoassay of GH, LH and PRL, and 
erythrocytes suspended in physiological saline were re- 
turned to the animals at the time of the next sample. Individ- 
ual rats were used as their own control, receiving control 
injections one experimental day and the drug(s) to be tested 
on a subsequent day. Animals received either the centrally 
active EPI synthesis inhibitors, SK&F 64139 and LY 78335, 
the peripherally active, SK&F 29661, or saline vehicle at 
0930 hr and were sampled for 3 hr or 6 hr beginning at 1000 
hr. The animals' behaviour was monitored through one-way 
observation ports in the cubicles. 
In a parallel experiment, male rats were killed by cervical 
dislocation 1.5, 2.5, and 3.5 hr after receiving either SK&F 
64139, 29661, or normal saline at 0930 hr. Their brains were 
removed immediately, and hypothalami were dissected, 
weighed, snap-frozen on dry ice, and stored at -90°C for 
subsequent extraction and determination of DA, NE, and 
EPI, as described previously [50]. 
Experiment 2. To investigate the effects of alpha- 
adrenergic receptor activation on GH after EPI depletion, 
clonidine (150 /zg/kg IV) or vehicle was given to SK&F 
64139-pretreated animals at 1105 hr by methods described 
for Experiment 1. 
Experiment 3. To determine whether blockade of central 
EPI synthesis affected morphine-stimulated GH, morphine 
sulfate (3 mg/kg IV) or normal saline was administered at 
1105 hr to animals pretreated with either SK&F 64139 or 
vehicle at 0930 hr. Samples were removed from 1000-1300 
hr, as described above. 
Experiment 4. Female rats were ovariectomized and al- 
lowed four weeks for recovery, during which time they were 
maintained on a 14 hr light/10 hr dark schedule and ad lib 
food and water. In a first experiment, the females received 
injections (SC) of either oil vehicle or 50/xg estradiol ben- 
zoate, followed 72 hr later by either oil vehicle again or by 2 
mg progesterone. Animals were sacrificed by cervical dislo- 
cation 6 hr after progesterone. Thirty minutes before and 2.5 
hr after progesterone or oil, animals received injections (IP) 
of either saline vehicle, or the centrally acting EPI synthesis 
inhibitors, SK&F 64139 (50 mg/kg) or SK&F 83593 (50 or 100 
mg/kg), or the peripherally active, SK&F 29661 (50 mg/kg). 
Plasma LH and PRL concentrations and hypothalamic cate- 
cholamines were measured in each group. 
Experiment 5. Ovariectomized females received estradiol 
followed by progesterone, as described above. Thirty min- 
utes prior to the progesterone, animals were given IP injec- 
tions of either saline or of 50 mg/kg of SK&F 64139. Two 
hours after progesterone, all animals received injections (IV) 
of either saline or of 100 ng of LHRH. Blood samples were 
taken 15 min after LHRH or saline and assayed for LH. 
Experiment 6. Ovariectomized females received injec- 
tions (SC) of either oil or estradiol at 1000 hr and were killed 
at 1600 hr on the next day, and plasma PRL concentrations 
were determined. Thirty minutes prior to estradiol, the 
females were treated (IP) with either saline or the EPI syn- 
thesis inhibitor, SK&F 64139 (50 mg/kg). These drug treat- 
ments were repeated at 2000, 0400 and 1200 hr. 
Pituitary Hormone Radioimmunoassays 
GH, LH and PRL were measured in duplicate by double 
antibody radioimmunoassays with materials supplied by the 
National Pituitary Agency, as described previously [7,52]. 
Values were determined using the weighted Rodbard method 
[52] and expressed in terms of their respective NIAMDD 
reference preparations. 
Catecholamine Assay 
Concentrations of EPI, NE, and DA in the hypothalamus 
were measured by a sensitive radioenzymatic assay, as de- 
scribed previously [7,50]. 
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FIG. 1. Effects of SK&F 29661, a peripheral EPI synthesis inhibitor, 
and SK&F 64139 on episodic GH secretion in individual male rats. 
Normal saline- and SK&F 29661-treated animals showed plulsatile 
GH release (top and middle, respectively). SK&F 64139 completely 
suppressed episodic GH secretion (bottom). The letter R followed 
by a number in the lower right corner of each graph refers to individ- 
ual rat code numbers in this and subsequent figures. 
Analysis of  Data 
Pituitary hormone and tissue catecholamine levels were 
compared using the appropriate analysis of variance and 
Newman-Keuls tests, as described previously [7,50]. p <0.05 
was considered significant. 
R E S U L T S  
Effects of  NMT Inhibitors on Episodic GH Secretion in Male 
and Ovariectomized Female Rats 
The pattern of GH secretion in individual animals con- 
firmed previous observations [49,52] that male rats kept on a 
constant light-dark cycle secrete GH at approximately the 
same time (Fig. 1, top). The centrally active SK&F 64139 
suppressed (p<0.001) pulsatile GH (Fig. 1, bottom) in a 
dose-dependent manner. Administration of the other cen- 
trally active EPI antagonist, LY 78335, also suppressed 
(p<0.001) GH release in a similar manner (not shown, 50). 
However, the peripheral NMT inhibitor, SK&F 29661, had 
no effect on GH when compared with the control group (Fig. 
1, middle). Similar effects on GH were observed in ovariec- 
tomized female rats (Fig. 2). 
As demonstrated previously [8, 45, 50], SK&F 64139 
caused a significant reduction (p <0.05) in the hypothalamic 
concentration of EPI in male rats from 1.5 to 3.5 hr after 
administration, whereas SK&F 29661 had no effect when 
compared to time-matched controls (Fig. 3). Neither of the 
drugs affected tissue levels of DA or NE (not shown, 50). 
To test whether the inhibition of GH release by SK&F 
64139 could be reversed by activation of central postsynaptic 
alpha-adrenergic receptors, clonidine or vehicle were ad- 
FIG. 2. Effects of SK&F 29661 and SK&F 64139 on episodic GH 
secretion in individual ovariectomized female rats. CNS NMT inhi- 
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FIG. 3. Effects of SK&F 29661 and SK&F 64139 on the concentra- 
tion of EPI in the hypothalamus 1.5, 2.5, and 3.5 hr after drug admin- 
istration at 0930 hr. SK&F 64139 caused a significant reduction in 
EPI, but 29661 had no significant effect. * indicates p<0.05. Eight 
animals were in each treatment group. Vertical lines represent SE in 
this and subsequent figures. 
ministered at a time (1105 hr) that coincided with the 
anticipated occurrence of a GH burst. In SK&F 64139- 
pretreated rats, clonidine caused a significant elevation in 
mean GH to levels seen during spontaneous pulses in un- 
treated animals (p<0.0001, Fig. 4). 
To determine whether EPI was involved in morphine- 
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FIG. 4. Effect of clonidine, a centrally active alpha-adrenergic 
agonist, on GH secretion in SK&F 64139-treated (0930 hr) male rats. 
Clonidine administration caused a significant elevation in GH levels. 
In this and subsequent figures, numbers in parentheses refer to the 
number of animals in each treatment group. Arrow indicates 
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FIG. 5. Effects of morphine on GH secretion in SK&F 64139- and 
saline-treated male rats. Morphine administration to saline-treated 
rats caused a significant elevation in GH levels. This effect was 
blocked completely by pretreatment with SK&F 64139. Arrow indi- 
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FIG. 6. Effects of the peripheral (SK&F 29661) and central (SK&F 
64139) EPI synthesis inhibitors on plasma PRL levels in male rats. 
Both drugs caused a significant elevation in plasma PRL. The cen- 
tral NMT inhibitor, LY 78335, did not elevate PRL above basal 
levels (not shown, 56). 
induced GH release, morphine sulfate (3 mg/kg IV) was ad- 
ministered to saline- or SK&F 64139-pretreated male rats. In 
the control group, morphine had an immediate stimulatory 
effect on GH that resulted in mean plasma levels >1,000 
ng/ml (Fig. 5). This stimulatory effect of morphine on GH 
was completely blocked by SK&F 64139. Morphine-induced 
GH release in the rat is inhibited by naloxone [19], indicating 
that this is a specific effect due to activation of opiate recep- 
tors. 
Effects o f  N M T  Inhibitors on PRL in Male Rats 
SK&F 64139 caused a significant increase in mean plasma 
levels of PRL (Fig. 6). Administration of the peripheral EPI 
synthesis inhibitor SK&F 29661 also elevated PRL levels 
(Fig. 6). However, the other central NMT inhibitor, LY 
78335, did not significantly alter plasma PRL levels com- 
pared to the control group (data not shown, 50). 
None of these drugs caused a discernible change in the 
animals' behavior, and, specifically, there were no indica- 
tions that the drug-treated animals were stressed. 
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FIG. 7. Episodic LH secretion over a 3 hr period in representative 
animals treated with saline or NMT inhibitors. Three-part number is 
animal identification code. Arrow denotes time of drug injection. 
Neither drug affected episodic LH release. 
Effects o f  N M T  Inhibitors on L H  and PRL Secretion in 
Ovariectomized Female Rats 
Representative 3 hr secretory prof'des of  LH in ovariec- 
tomized, hormonally untreated rats administered either 
saline, S K & F  64139 or 29661 are illustrated in Fig. 7. Pulses 
of LH secretion were defined by criteria described previ- 
ously [7]. Rats showed typical pulsatile LH secretion as de- 
scribed elsewhere [7]. Neither NMT inhibitor significant- 
ly affected the frequency or  the mean pulse amplitude of  
LH pulses during the 3 hr sampling period. 
The administration of progesterone to estrogen- 
pretreated animals elicited a surge of  LH in saline controls 
(Fig. 8). This was completely blocked by the centrally acting 
EPI synthesis inhibitor, S K & F  64139, and was also antago- 
nized in a dose-related manner by S K & F  83593, a second 
centrally acting EPI antagonist. 
However ,  S K & F  29661, the EPI synthesis inhibitor that 
fails to cross the blood brain barrier [8,40], had no effect on 
the ovarian hormone-induced L H  surge. None of  the drugs 
tested altered "res t ing"  levels of LH in oil vehicle-treated 
controls. S K & F  64139 and 83593 significantly reduced hypo- 
thalamic concentrations of  EPI in EB + progesterone- 
treated animals, but did not affect NE or DA levels, as de- 
scribed elsewhere [7]. 
S K & F  64139 did not block the LH surge by inhibiting the 
t [ ]  LH 
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FIG. 8. Concentrations of LH and PRL in plasma of ovariectomized 
rats given oil plus saline or estradiol (EB) and progesterone (PROG) 
plus saline or NMT inhibitors, tp0.01 vs oil-saline; **p<0.01 vs EB 
+ PROG and saline, based on analyses of variance and Newman- 
Keuls tests, n's=8-10. 
TABLE 1 
EFFECTS OF SK&F 64139 ON LHRH-INDUCED LH RELEASE AFTER 
SEQUENTIAL ADMINISTRATION OF ESTRADIOL AND 
PROGESTERONE 
LH RP-I 
Treatments +-SE (ng/ml)t 
1. Saline (IP) + Saline (IV) 
2. Saline (IP) + LHRH 
(100 lag IV) 
3. SK&F 64139 (50 mglkg IP) + LHRH 
(100 ng IV) 
227 ± 23 
628 ±60* 
520 ± 27* 
*p<0.01 vs saline (IP) + saline (IV); tblood samples taken 15 min 
after LHRH or saline (IV); n's=6. 
response of  gonadotropin-secreting cells to LHRH. Table 1 
shows that circulating LH was markedly elevated 15 min 
after IV administration of LHRH,  and that this effect was 
not significantly altered by pretreatment with the EPI syn- 
thesis inhibitor. 
In contrast  to the inhibitory effects of  the EPI synthesis 
inhibitors on LH, these compounds had no effect on the 
steroid-induced increase in PRL (Fig. 8). However,  because 
this increase of  PRL is largely a consequence of  the estradiol 
administered 3 days earlier, the third study tested whether 
S K & F  64139 would prevent an acute rise in PRL induced by 
treatment with estradiol alone. As shown in Table 2, the EPI 
synthesis inhibitor did not block, and in fact tended to aug- 
ment, the small rise in PRL observed on the day after estro- 
gen treatment. 
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TABLE 2 
EFFECTS OF SK&F 64139 ON ESTRADIOL,INDUCED PLASMA PRL IN 
OVARIECTOMIZED RATS 
PRL RP-1 
Treatments -SE (ng/ml) 
1. Oil + Saline 
2. Estradiol + Saline 
3. Estradiol + SK&F 64139 
3.9 _+ 0.8 
20.0 _ 1.1" 
41.2 _+ 7.2t 
*p<0.05 vs Oil + Saline; tp<0.01 vs Oil + Saline, p<0.05 vs 
Estradiol + Saline; n's=8; blood samples were taken 4 hr after 
the last injection of saline or SK&F 64139. 
DISCUSSION 
Growth Hormone 
The results of this study show that inhibition of CNS EPI 
synthesis by SK&F 64139 and LY 78335 completely sup- 
pressed physiologic, episodic GH release in male and female 
rats. In contrast, the peripheral EPI synthesis blocker, 
SK&F 29661, had no effect on GH secretion. The inhibition 
of episodic GH secretion by SK&F 64139 was accompanied 
by a significant reduction in the hypothalamic concentration 
of EPI, whereas SK&F 29661 had no effect. Earlier studies 
have shown that LY 78335 inhibited hypothalamic EPI syn- 
thesis [10]. These findings indicate that inhibition of CNS 
EPI synthesis rather than adrenal EPI synthesis is responsi- 
ble. 
In man, peripheral administration of EPI in doses suffi- 
cient to produce significant hyperglycemia did not induce 
GH release [31, 42, 46]. In contrast, large doses of EPI 
caused an increase in plasma GH levels in rhesus monkeys 
[32]. Intracerebroventricular or intravenous EPI administra- 
tion to rats also caused release of bioassayable GH [36,37]. 
However, these experiments were limited by the poor penet- 
rability of the blood-brain barrier by EPI and the unavaila- 
bility of agents that directly affect brain EPI neurotransmis- 
sion. Data from the present experiments, in which selective 
EPI antagonists were used, indicate that the central EPI sys- 
tem has a major function in the generation of episodic GH 
secretion in the rat. 
Inhibition of GH secretion by CNS EPI synthesis block- 
ade could be due to decreased GH-releasing factor or in- 
creased SRIF release. Recent data [53] favor the former 
hypothesis because passive immunization against circulating 
SRIF did not reverse SK&F 64139-induced TSH suppres- 
sion, and previous studies have shown the TSH response to 
SRIF antiserum, which was inhibited by SK&F 64139 [53], is 
mediated by thyrotropin releasing hormone [4]. 
Previous studies have shown that clonidine restores pulsa- 
tile GH release in male rats after blockade of NE and EPI 
synthesis with FLA-63, a DA-beta-hydroxylase inhibitor 
[51]. In the present study, clonidine administration to NMT- 
inhibited animals elevated GH to levels that occur during 
episodic release. Clonidine also stimulates GH secretion in 
man and several species of experimental animals [3, 9, 24, 
26, 51]. The stimulatory action of clonidine is most likely due 
to activation of postsynaptic alpha-adrenergic receptors. 
Clonidine activates postsynaptic or presynaptic EPI recep- 
tors in discrete brain regions [11]. It is not possible at present 
to determine whether the effect of clonidine is due to activa- 
tion of receptors normally occupied by NE or EPI. How- 
ever, the ability of clonidine to stimulate GH release in 
NMT-inhibited rats demonstrates that the EPI synthesis in- 
hibitor, SK&F 64139, does not compromise the ability of the 
pituitary gland to release GH. 
Morphhae and the endogenous opioid peptides, meten- 
kephalin and beta-endorphin, have a potent stimulatory ef- 
fect on GH secretion in numerous experimental animals, an 
effect prevented by the specific opiate receptor blocker, 
naloxone [5, 15, 19, 29, 54]. Furthermore, the synthetic 
enkephalin analogue, FK-33-824, causes GH release in man 
[13]. None of the opioids appear to act directly at the pitui- 
tary level, and it is likely that they influence the release of 
GH either by modulating the secretion of releasing-inhibiting 
factors and/or by influencing monoaminergic neurotrans- 
mission [41]. Evidence to support the latter hypothesis was 
provided in a recent study demonstrating that alpha- 
adrenergic receptor blockade with phenoxybenzamine or 
inhibition of NE and EPI synthesis with diethyldithiocarba- 
mate, a DA-beta-hydroxylase inhibitor, abolished the GH- 
releasing effect of morphine on GH in the rat [19]. These 
effects were attributed to noradrenergic mechanisms. Data 
from the present study suggest that morphine enhances GH 
secretion by activation of CNS EPI systems, because the 
selective EPI antagonist, SK&F 64139, completely blocked 
morphine-induced GH release. These results do not neces- 
sarily exclude a similar role for NE. 
Prolactin 
The tetrahydroisoquinoline NMT inhibitors, SK&F 64139 
and 29661, both elevated plasma PRL levels. The mechanism 
underlying this effect is unknown but does not appear to be 
related to EPI synthesis inhibition, because elevation of PRL 
was not observed with the benzylamine NMT inhibitor, LY 
78335. It is possible that the SK&F compounds exert a direct 
action on pituitary lactotrophs (i.e., DA receptor blockade) 
unrelated to their effects on EPI synthesis. 
Luteinizing Hormone 
The present results suggest that the stimulatory feedback 
actions of the ovarian hormones on LH release may be 
mediated by activation of the central epinephrine-containing 
systems. The lack of an inhibitory effect by SK&F 29661, 
which does not inhibit EPI synthesis in the brain, and the 
failure of SK&F 64139 to block LH release elicited by exog- 
enous LHRH point to a central site of action for the drugs. 
The present experiments do not necessarily rule out a similar 
role for norepinephrine but they do appear to indicate that 
EPI may be of primary importance in regulation of LH se- 
cretion. 
This hypothesis was further tested in EPI turnover 
studies (manuscript in preparation). A decline of hypotha- 
lamic EPI was observed after c~-methyltyrosine in estrogen 
plus progesterone-treated animals, as compared to the vehi- 
cle controls, while estrogen alone had no effect. Because the 
depletion of catecholamine after a-methyltyrosine depends 
upon the rate of nerve impulse flow, with more decline as- 
sociated with increased neuronal activity [I], these results 
may be interpreted to mean that estradiol plus progesterone 
treatment enhances the turnover of EPI in the hypothalamus 
during the LH surge. These findings are, therefore, consis- 
tent with the hypothesis that the stimulatory feedback effects 
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of  the ovar ian hormones  on L H  may involve act ivat ion of  
epinephrine systems.  
It  is possible that EPI  neurons  stimulate e i ther  direct ly  o r  
indirectly,  the release o f  L H R H .  In addit ion to enhancing 
hypothalamic  EPI  turnover ,  the administrat ion o f  estradiol  
and proges terone  produced  sequential  accumula t ion  fol- 
lowed by a decline of  L H R H  in the median eminence  and 
arcuate  nucleus prior to the L H  surge [47], and there  is evi-  
dence  for release of  L H R H  into the pituitary portal  system at 
this t ime [44]. Fur ther  invest igat ions are cont inuing to test  
whe the r  EPI  synthesis inhibitors prevent  these  ovar ian 
hormone- induced  changes in L H R H .  I f  so, this could be 
cons idered  ev idence  that  central  EPI  systems regulate the 
neurosecre t ion  o f  L H R H .  
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